Montage Technology (688008.SH) independent directors propose repurchasing 300 million to 500 million yuan of the company's A-shares.
Montage Technology (688008.SH) announced that on October 16, 2026, the company's board of directors received a letter from the company's independent director, Mr. YUHUA CHENG (), titled "Letter Regarding the Proposal to Montage Technology Co., Ltd. to Repurchase the Company's A-Shares." Mr. YUHUA CHENG () proposed that the company repurchase its A-shares through centralized bidding transactions using its own funds. Total funds for the share repurchase: no less than RMB 300 million (inclusive), and no more than RMB 500 million (inclusive). The repurchased shares will be used in full for an employee stock ownership plan or equity incentive at an appropriate time in the future.
Montage Technology (688008.SH) announced that on October 16, 2026, the company's board of directors received a letter from the company's independent director Mr. YUHUA CHENG (), "Proposal Regarding the Repurchase of Montage Technology Co., Ltd.'s A-Shares." Mr. YUHUA CHENG () proposed that the company repurchase its A-shares through centralized bidding transactions using its own funds. Total funds for the share repurchase: no less than RMB 300 million (inclusive) and no more than RMB 500 million (inclusive). The repurchased shares will be used in full for an employee stock ownership plan or equity incentive at an appropriate time in the future.
Related Articles
Willing New Energy(002667.SZ): Shannan Antimony Gold will become the company's largest shareholder
Founder: The market bottoming area is gradually becoming clear; focus on three aspects of allocation opportunities.
Mabwell (688062.SH): 9MW2821 will present clinical data in an oral presentation at the 2026 ESMO Congress.
Willing New Energy(002667.SZ): Shannan Antimony Gold will become the company's largest shareholder
Founder: The market bottoming area is gradually becoming clear; focus on three aspects of allocation opportunities.
Mabwell (688062.SH): 9MW2821 will present clinical data in an oral presentation at the 2026 ESMO Congress.
